# The multifaceted role of AIF-1 in metabolic dysregulation: bridging inflammation, insulin resistance, and obesity

## TL;DR

This paper explores how AIF-1 influences obesity, inflammation, and insulin resistance, highlighting its potential as a therapeutic target.

## Contribution

The paper provides new insights into AIF-1's dual role in obesity regulation and its broader implications for metabolic and inflammatory diseases.

## Key findings

- Elevated AIF-1 levels correlate with obesity and inflammation.
- Reduced AIF-1 promotes weight loss by regulating MAOA and decreasing leptin/resistin.
- AIF-1 influences macrophage activity in adipose tissue, affecting obesity outcomes.

## Abstract

Allograft inflammatory factor-1 (AIF-1), a cytokine secreted by activated monocytes, macrophages, and lymphocytes, has emerged as a critical regulator of pathological processes spanning renal diseases, rheumatoid arthritis, cancer, cardiovascular disorders, neurological pathologies, and transplant-related conditions. Population-based studies have associated sequence variants near the AIF-1 locus with obesity, though AIF-1’s potential pathophysiological involvement remains uninvestigated. Understanding its molecular characteristics, receptor interactions, and signaling pathways is essential for elucidating its biological functions. This review comprehensively examines AIF-1’s involvement in inflammatory and metabolic pathogenesis, particularly focusing on obesity and inflammation. Through systematic literature analysis, we consolidated current knowledge on AIF-1’s functions and analyzed studies exploring its roles in obesity, insulin resistance, and inflammation to clarify broader disease mechanisms. AIF-1 exerts pleiotropic effects on immune cells, insulin signaling, and adipocytes. Elevated AIF-1 levels correlate with inflammatory adipocytes and obesity, while reduced AIF-1 promotes weight loss through regulation of monoamine oxidase A and decreased leptin/resistin production. Deciphering AIF-1’s complex roles in inflammation and metabolic disorders offers critical insights for therapeutic development. Targeting AIF-1 or AIF1-like (AIF1L) may yield novel strategies to mitigate disease progression and enhance clinical management of obesity.

The dual role of AIF-1 in obesity. Enhanced AIF-1 mediates obesity. Loss of AIF-1 induces obesity resistance. AIF-1, allograft inflammatory factor-1; MAOA, monoamine oxidase a; WAT, white adipose tissue; IR, insulin resistance.Diagram illustrating the role of AIF-1 in obesity regulation in mice. On the left, AIF-1 loss leads to macrophages as a regulator of MAOA expression, resulting in adipose tissue and resistance to obesity. On the right, AIF-1 increase involves macrophages for regulation of WAT expression, leading to adipose tissue and obesity, represented by arrows and color-coded labels.

The dual role of AIF-1 in obesity. Enhanced AIF-1 mediates obesity. Loss of AIF-1 induces obesity resistance. AIF-1, allograft inflammatory factor-1; MAOA, monoamine oxidase a; WAT, white adipose tissue; IR, insulin resistance.